Ivonescimab’s progression-free survival data in non-small cell lung cancer bode well for an upcoming overall survival readout ...

After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in ...

If approved in RCC, fruquintinib will be available for three indications, including endometrial and colorectal cancer.

Ivonescimab combined with chemotherapy significantly improved progression-free survival (PFS) compared with Tevimbra ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio PARK CITY, Utah — In this Healio Video ...

Camrelizumab and famitinib are projected to achieve global annual sales of $463 million and $108 million by 2031.

Please provide your email address to receive an email when new articles are posted on . Used in association with the classic VEGF-A antagonists, this new drug could provide complete protection against ...

New study data indicate that VEGF inhibition suppressed angiotensin converting enzyme 2 (ACE2), a component of the renin-angiotensin system that has antitumor activity, in a mouse model of clear cell ...

A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated ...

BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly ...

EyePoint (EYPT) announced details for its pivotal Phase 3 program evaluating Duravyu for the treatment of diabetic macular edema with first ...